HIV infects a type of white blood cell called a T-helper cell (also called a CD4 cell) in the body's immune system. By fighting off diseases and illnesses, these vital cells keep us safe. HIV is not able to replicate by itself. The virus attaches itself to a T-helper cell instead, and fuses (joins together) with it. It then takes control of the DNA of the cell, makes copies of itself within the cell and eventually releases more HIV into the blood. HIV will begin to propagate and grow across the body – a phase called the HIV lifecycle. A variety of different types of drugs are combined in antiretroviral therapy for HIV, each of which targets a different stage in the lifecycle of HIV. This means that HIV replication on multiple fronts is halted, making it very successful. If taken correctly, it keeps the immune system safe, avoids the development of AIDS-related symptoms and diseases, and ensures people can lead long and healthy lives. HIV is an insidious virus with extraordinary expertise for survival. It targets the CD4 cells of the human immune system, a significant player in the body's defence against pathogens. While drugs have been developed that suppress the virus, it is still able to hide in the genome, ready to emerge at any time and cause illness. If a case of HIV is to be fully healed, it must kill certain latent viral reservoirs. Otherwise, patients with HIV must continue to take medicines which keep the virus at bay. HIV binds to a T-helper cell. It then binds to it and releases the cell with its genetic material. Fusion or entry inhibitor drugs are considered the types of drugs that interrupt this step of the lifecycle because they interrupt HIV from entering the cell. HIV transforms the genetic material into HIV DNA once within the T-helper cell, a process that is called reverse transcription. The fresh HIV DNA then enters and takes charge of the host cell's nucleus. Nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and integrase inhibitor drugs are the types of drugs that interrupt this step of the lifecycle. The infected T-helper cell then produces HIV proteins which are used within the cell to create more HIV particles. The new HIV is assembled and then released into the bloodstream from the T-helper cell to infect other cells, and so the process starts again. Protease inhibitor (PI) drugs are the sort of drugs that interrupt this step of the lifecycle. This review tells about the future scope of the new invention towards the field of HIV /AIDS and their medicinal treatment. People who are interested can send their article towards our journal for publication through this https://www.scholarscentral.org/submissions/hiv-aids-research.html